Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Revlimid (lenalidomide) has been recommended for use with Roche’s MabThera (rituximab) – also known as R2 regimen – for the treatment of adult patients with previously-treated grade 1 to 3A follicular ... Revlimid plus MabThera demonstrated a

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Roche posts minor sales miss in Q4 as biosimilar pressure grows All told, the Swiss group’s pharma sales came in at CHF 12bn ($12.35bn), with its ‘big three’ antibodies – Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab) – all on the

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan, Biocon’s Herceptin biosimilar launched in US Alongside Herceptin, this includes Avastin (bevacizumab) and MabThera (rituximab) which are also under threat from new biosimilar launches.

ChemoCentryx surges on phase 3 vasculitis study

ChemoCentryx surges on phase 3 vasculitis study At the moment ANCA vasculitis is treated with a combination of potent steroids like prednisolone with immunosuppressive drugs like cyclophosphamide or Roche’s Rituxan/MabThera (rituximab).

Teva names new CFO and bulks up its opioid liability fund

Teva names new CFO and bulks up its opioid liability fund One bright spot for the company this week was the US launch of Celltrion-partnered Truxima – the first biosimilar of Roche’s big-selling Rituxan (rituximab) to reach the US market – ... rheumatoid arthritis, Teva and Celltrion’s drug is expected

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Why we need to improve diverse representation in clinical trials
Diversity in clinical trials: The powerful need to improve it! “One size fits all” is rapidly becoming an outdated concept in modern-day life, and medical research is no exception. Without...

Infographics